NO20022065L - Terapeutisk anvendelse - Google Patents

Terapeutisk anvendelse

Info

Publication number
NO20022065L
NO20022065L NO20022065A NO20022065A NO20022065L NO 20022065 L NO20022065 L NO 20022065L NO 20022065 A NO20022065 A NO 20022065A NO 20022065 A NO20022065 A NO 20022065A NO 20022065 L NO20022065 L NO 20022065L
Authority
NO
Norway
Prior art keywords
therapeutic use
patient
chemoprevention
onset
effective amount
Prior art date
Application number
NO20022065A
Other languages
English (en)
Other versions
NO20022065D0 (no
NO323206B1 (no
Inventor
Nigel James Bundred
Original Assignee
Univ Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manchester filed Critical Univ Manchester
Publication of NO20022065D0 publication Critical patent/NO20022065D0/no
Publication of NO20022065L publication Critical patent/NO20022065L/no
Publication of NO323206B1 publication Critical patent/NO323206B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20022065A 1999-11-02 2002-04-30 Anvendelse av EGFR-tyrosinkinase-inhibitor for fremstilling av et medikament, og et medisinsk testsett som omfatter en EGFR-tyrosinkinase-inhibitor NO323206B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9925958.2A GB9925958D0 (en) 1999-11-02 1999-11-02 Therapeutic use
PCT/GB2000/004190 WO2001032155A2 (en) 1999-11-02 2000-11-01 Use of egfr tyrosine kinase inhibitors for treating breast cancer

Publications (3)

Publication Number Publication Date
NO20022065D0 NO20022065D0 (no) 2002-04-30
NO20022065L true NO20022065L (no) 2002-06-24
NO323206B1 NO323206B1 (no) 2007-01-22

Family

ID=10863835

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022065A NO323206B1 (no) 1999-11-02 2002-04-30 Anvendelse av EGFR-tyrosinkinase-inhibitor for fremstilling av et medikament, og et medisinsk testsett som omfatter en EGFR-tyrosinkinase-inhibitor

Country Status (21)

Country Link
US (1) US7553815B1 (no)
EP (1) EP1272188B1 (no)
JP (1) JP2003513035A (no)
KR (1) KR100785359B1 (no)
CN (1) CN1197577C (no)
AT (1) ATE339957T1 (no)
AU (1) AU779190B2 (no)
BR (1) BR0015194A (no)
CA (1) CA2389411C (no)
CY (1) CY1106285T1 (no)
DE (1) DE60030889T2 (no)
DK (1) DK1272188T3 (no)
ES (1) ES2275556T3 (no)
GB (1) GB9925958D0 (no)
IL (1) IL149176A0 (no)
MX (1) MXPA02004272A (no)
NO (1) NO323206B1 (no)
NZ (1) NZ518696A (no)
PT (1) PT1272188E (no)
WO (1) WO2001032155A2 (no)
ZA (1) ZA200203431B (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
CN1447696A (zh) 2000-05-19 2003-10-08 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
WO2003000188A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
US20050038048A1 (en) * 2001-10-29 2005-02-17 Ball Howard Ashley Use of 7h-pyrrollo{2,3-d}pyrimidine derivatives in the treatment of solid tumor diseases
AU2002351196A1 (en) * 2001-12-03 2003-06-17 Bayer Pharmaceuticals Corporation Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
EP1837025A3 (en) * 2002-06-05 2007-12-19 Cedars-Sinai Medical Center Method of treating cancer using kinase inhibitors
WO2005017493A2 (en) * 2003-08-15 2005-02-24 Smithkline Beecham Corporation Biomarkers in cancer
MXPA06003113A (es) 2003-09-19 2006-06-20 Astrazeneca Ab Derivados de quinazolina.
WO2005039588A2 (en) * 2003-10-22 2005-05-06 Novartis Ag Methods for determining the risk of developing liver and lung toxicity
US7701341B2 (en) * 2004-09-01 2010-04-20 Microsoft Corporation Device service provider interface
ES2710439T3 (es) 2005-01-21 2019-04-25 Genentech Inc Dosificación fija de anticuerpos HER
KR101253576B1 (ko) 2005-02-23 2013-04-11 제넨테크, 인크. Ｈｅｒ 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장
CN101003514A (zh) * 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途
EP1982718A4 (en) 2006-02-09 2010-05-12 Daiichi Sankyo Co Ltd PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF CANCER
CN1899616A (zh) * 2006-07-20 2007-01-24 中国人民解放军军事医学科学院生物工程研究所 非受体酪氨酸激酶c－Abl特异性抑制剂的新用途
EP2899541A1 (en) 2007-03-02 2015-07-29 Genentech, Inc. Predicting response to a HER dimerisation inhbitor based on low HER3 expression
CA2690334C (en) 2007-06-08 2017-02-14 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
SG174272A1 (en) * 2009-03-11 2011-10-28 Ardea Biosciences Inc Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers
SG10201402742YA (en) 2009-03-20 2014-08-28 Genentech Inc Bispecific anti-her antibodies
JP5705836B2 (ja) 2009-05-29 2015-04-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ２を発現する胃癌患者のｈｅｒ２シグナル伝達のためのモジュレーター
KR20130000384A (ko) 2010-02-18 2013-01-02 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 뉴레귤린 길항제 및 암의 치료에서의 그의 용도
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
US20140363438A1 (en) 2011-08-17 2014-12-11 Genentech, Inc. Neuregulin antibodies and uses thereof
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
AU2012346540C1 (en) 2011-11-30 2019-07-04 Genentech, Inc. ErbB3 mutations in cancer
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
RU2014136886A (ru) 2012-03-27 2016-05-20 Дженентек, Инк. Диагностика и виды лечения, связанные с ингибиторами her3
JP6998646B2 (ja) 2012-11-30 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ－ｌ１阻害剤併用療法を必要とする患者の同定
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5795910A (en) * 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
DE69536015D1 (de) * 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
EP0831829B1 (en) * 1995-06-07 2003-08-20 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
EP0836605B1 (en) * 1995-07-06 2002-02-06 Novartis AG Pyrrolopyrimidines and processes for the preparation thereof
WO1999060023A1 (en) * 1998-05-15 1999-11-25 Imclone Systems Incorporated Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
US20090202167A1 (en) 2006-08-28 2009-08-13 Koninklijke Philips Electronics N.V. Method and apparatus for image enhancement

Also Published As

Publication number Publication date
DE60030889D1 (de) 2006-11-02
KR20020064306A (ko) 2002-08-07
DK1272188T3 (da) 2007-01-29
IL149176A0 (en) 2002-11-10
NO20022065D0 (no) 2002-04-30
KR100785359B1 (ko) 2007-12-18
ES2275556T3 (es) 2007-06-16
NO323206B1 (no) 2007-01-22
EP1272188A2 (en) 2003-01-08
ATE339957T1 (de) 2006-10-15
DE60030889T2 (de) 2007-04-05
NZ518696A (en) 2004-12-24
CA2389411A1 (en) 2001-05-10
PT1272188E (pt) 2007-01-31
MXPA02004272A (es) 2003-08-20
EP1272188B1 (en) 2006-09-20
WO2001032155A2 (en) 2001-05-10
AU1155901A (en) 2001-05-14
ZA200203431B (en) 2003-02-26
CN1197577C (zh) 2005-04-20
JP2003513035A (ja) 2003-04-08
CN1387437A (zh) 2002-12-25
CA2389411C (en) 2009-09-01
WO2001032155A3 (en) 2002-05-10
GB9925958D0 (en) 1999-12-29
US7553815B1 (en) 2009-06-30
AU779190B2 (en) 2005-01-13
CY1106285T1 (el) 2011-10-12
BR0015194A (pt) 2002-06-18

Similar Documents

Publication Publication Date Title
NO20022065D0 (no) Terapeutisk anvendelse
TR200201442T2 (tr) Ağrı hafifletme, kemik kanseri terapisi ve kemik yüzeyinin sağlıklı tutulması için kireçlenmiş hedef dokulara yönelik radyum-223 hazırlanması ve kullanımı.
DK1565471T3 (da) Quionolinylpyrazoler
ATE307601T1 (de) Brustkrebsbehandlung mittels natürlicher ätherischer öle
PT1223980E (pt) Utilizacao de inibidores de csf-1
CY1112753T1 (el) Θεραπευτικη αγωγη καρκινων του ανθρωπινου σωματος με τη χρηση toy ετ743
MY138059A (en) Use of ikb-kinase inhibitors in pain therapy
NO20032027D0 (no) Effektive antitumorbehandlinger
PT1390371E (pt) Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores
SE9802208D0 (sv) Novel compounds
ATE313334T1 (de) Behandlung von tumoren mit photodynamischer therapie
ATE297751T1 (de) Kombinationstherapie mit keratinozyten- wachstumfaktor und ein epidermis-wachstumfaktor inhibitor
SE9802209D0 (sv) Novel compounds
SE9902597D0 (sv) New use
MX2007006927A (es) Combinacion de inhibidor de tirosina cinasa y her-2/neu para terapia de cancer.
GEP201606538B (en) Preoperative treatment of post operative pain
ATE330600T1 (de) Kombinationspräparat zur krebstherapie
PL367707A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
DK1150981T3 (da) Terapeutisk necleosidforbindelse
DE60234995D1 (de) Tatakrebs
DE60316927D1 (de) Verwendung von devazepide als schmerzmittel
EA200600987A1 (ru) Применение сирамезина в лечении злокачественных опухолей
UA37750A (uk) Спосіб лікування запальних захворювань пародонту у вагітних жінок

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees